| scholarly article | Q13442814 |
| P2093 | author name string | Ryan M | |
| Johnson DA | |||
| Willis J | |||
| Brooks W | |||
| Stacy T | |||
| Hornbuckle K | |||
| Doviak M | |||
| Wootton T | |||
| P2860 | cites work | Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease | Q31404948 |
| Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease | Q34523308 | ||
| Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole | Q43742706 | ||
| Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis | Q43939369 | ||
| Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers | Q44703399 | ||
| Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study | Q45009904 | ||
| Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms | Q45045271 | ||
| Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis | Q45264297 | ||
| Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. | Q52067661 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | esomeprazole | Q553223 |
| P304 | page(s) | 129-134 | |
| P577 | publication date | 2005-07-01 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease | |
| P478 | volume | 22 |
| Q37160360 | A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD). |
| Q42170103 | Clinical trial: intragastric acid control in patients who have Barrett's oesophagus--comparison of once- and twice-daily regimens of esomeprazole and lansoprazole |
| Q37390644 | Esomeprazole: a proton pump inhibitor |
| Q37032564 | Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults |
| Q37588492 | Insights into the future of gastric acid suppression |
| Q46830968 | Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults. |
| Q82387739 | Nocturnal acid breakthrough on proton pump inhibitor therapy: to treat or not to treat |
| Q36542670 | Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. |
| Q37235086 | Proton pump inhibitors: an update of their clinical use and pharmacokinetics |
| Q35993040 | Rapid progressive long esophageal stricture caused by gastroesophageal reflux disease after pylorus-preserving pancreatoduodenectomy |
| Q37299839 | Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. |
| Q36319536 | Review article: putting immediate-release proton-pump inhibitors into clinical practice--improving nocturnal acid control and avoiding the possible complications of excessive acid exposure |
| Q26849521 | Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection |
| Q46878264 | The anti-secretory and anti-ulcer activities of esomeprazole in comparison with omeprazole in the stomach of rats and rabbits |
| Q49860893 | The role of pH in symptomatic relief and effective treatment of gastroesophageal reflux disease |
| Q46907607 | Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial |